Search

Search Constraints

You searched for: Author/Creator Kurosaki, Masayuki

Search Results

21. Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. Issue 10 (10th July 2019)

22. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. Issue 9 (17th May 2018)

23. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group. Issue 7 (18th May 2022)

24. Evidence‐based clinical practice guidelines for liver cirrhosis 2020. Issue 7 (6th July 2021)

25. General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy. Issue 7 (8th June 2022)

26. Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. Issue 1 (January 2016)

27. Hepatitis B core‐related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen‐negative chronic hepatitis B patients. Issue 10 (16th June 2021)

28. Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir. Issue 3 (24th October 2019)

29. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Issue 3 (22nd October 2021)

30. Hepatocellular carcinoma risk assessment using gadoxetic acid‐enhanced hepatocyte phase magnetic resonance imaging. Issue 13 (24th April 2014)